| Company name (CEO name) | Compensation in million U.S. dollars |
|---|---|
| Merck & Co. (Ken Frazier) | 20.9 |
| Johnson & Johnson (Alex Gorsky) | 20.1 |
| Pfizer (Ian Read) | 19.5 |
| Bristol-Myers Squibb (Giovanni Caforio) | 19.4 |
| Eli Lilly (David Ricks) | 17.2 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
May 2019
More information
Region
Worldwide
Survey time period
2018
Number of respondents
base: 200 life sciences companies
Special properties
large pharmaceutical companies
Supplementary notes
For the report, BioPharma Dive explicitly grouped firms in these 3 categories:
Large cap biotech: Market capitalization greater than $10 billion.
Mid-sized biotech: Market capitalization between $2 billion and $10 billion.
Small biotech: Market capitalization between $500 million and $2 billion.
This statistic is for large companies worth more than $10 billion.
CEO compensation includes base salary, cash bonuses and long-term
stock and option awards, as described in annual proxy filings.
Citation formats
